Iterum Therapeutics

NASDAQ: ITRM · Real-Time Price · USD
0.85
0.03 (3.66%)
At close: Aug 15, 2025, 10:23 AM

Iterum Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
254K 1.75M 1.8M n/a
Gross Profit
-254K -1.75M -1.8M -2.1M
Operating Income
-18.7M -47.47M -30.38M -24.54M
Interest Income
n/a 1.43M 2.36K 4.53K
Pretax Income
-24.53M -37.76M -44.13M -90.86M
Net Income
-24.77M -38.37M -44.43M -91.56M
Selling & General & Admin
7.98M 7.48M 12.77M 13.82M
Research & Development
10.46M 39.99M 17.62M 10.71M
Other Expenses
n/a n/a -16.85M 195K
Operating Expenses
18.44M 47.47M 30.38M 24.54M
Interest Expense
n/a 1.43M 2.36M 5.55M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
18.7M 47.47M 30.38M 24.54M
Income Tax Expense
240K 613K 301K 705K
Shares Outstanding (Basic)
19.7M 12.96M 12.24M 10.89M
Shares Outstanding (Diluted)
19.7M 12.96M 12.24M 10.89M
EPS (Basic)
-1.26 -2.96 -3.63 -8.41
EPS (Diluted)
-1.26 -2.96 -3.63 -8.41
EBITDA
-18.7M -34.58M -39.97M -83.2M
EBIT
-18.7M -36.33M -41.77M -85.31M
Depreciation & Amortization
284K 1.75M 1.8M 2.1M